NCT03283098View on ClinicalTrials.gov

A Phase 1 Study to Evaluate PK, Safety and Tolerability of AMG 416

PHASE1CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

March 1, 2018

Primary Completion Date

February 4, 2019

Study Completion Date

February 4, 2019

Conditions
Secondary Hyperparathyroidism
Interventions
DRUG

Etelcalcetide

Etelcalcetide was supplied as a sterile, preservative-free, aqueous solution in a single-use 3 mL glass vial.

DRUG

Placebo

Placebo supplied to match active intervention.

Trial Locations (5)

100044

Research Site, Beijing

200032

Research Site, Shanghai

200040

Research Site, Shanghai

200127

Research Site, Shanghai

210029

Research Site, Nanjing

Sponsors

Lead Sponsor

Amgen
All Listed Sponsors
lead

Amgen

INDUSTRY

NCT03283098 - A Phase 1 Study to Evaluate PK, Safety and Tolerability of AMG 416 | Biotech Hunter | Biotech Hunter